No price history available.
Key financial summary
Financials in KRW| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | KRWm | 1,619,865 | 1,687,810 | 1,775,847 | 1,858,984 | 2,067,791 | 2,186,638 | N/A | N/A |
| Operating profit | KRWm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net profit | KRWm | 192,761 | 102,583 | 95,144 | 136,198 | 70,687 | 194,079 | N/A | N/A |
| EPS reported | KRW | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating cashflow per share | KRW | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Capex per share | KRW | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF per share | KRW | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Free cash flow | KRWm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt | KRWm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value equity | KRWm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value per share | KRW | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Number of shares | m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| DPS (TTM paid) | KRW | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Financial summary
Financials in KRW| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/B LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/S LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/FCF LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/EBITDA LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/Sales LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Earnings Yield LTM | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Quality | |||||||||
| ROE | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| ROIC | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Sales | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Growth and momentum | |||||||||
| EPS Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Sales Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Income Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating Profit Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend and capital structure | |||||||||
| Dividend Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Payout Ratio | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Debt | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Debt/EBITDA | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EBIT/Net interest | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/market cap | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/Equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross debt/equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Yuhan Corporation is a global pharmaceutical enterprise specializing in the research, development, and manufacturing of active pharmaceutical ingredients (APIs) and intermediate compounds, with operations spanning South Korea and international markets. Its extensive product portfolio includes a diverse range of pharmaceuticals such as antivirals, antibiotics, antihistamines, antidiabetics, beta-lactamase inhibitors, CNS intermediates, and PEGylated compounds. A notable offering is Revanex, an acid pump antagonist used to treat peptic ulcers and gastritis-related mucosal damage. The company also provides ethical drugs (ETC) targeting multiple therapeutic areas, including cardiovascular, digestive, genito-urinary, metabolic, respiratory, allergy, and neurological systems, alongside anti-infectives, anti-cancer treatments, hormone therapies, analgesics, anti-rheumatics, and anesthetics. Beyond prescription medications, Yuhan also markets over-the-counter (OTC) items, encompassing vitamins, minerals, liver support medications, tonics, and remedies for respiratory, digestive, dermatological, and pain conditions. Furthermore, it supplies household and personal care goods, such as cleaning agents (bleaches, detergents), pest control products, and oral hygiene solutions. The corporation maintains a dental division, supplying implants, dental equipment, consumables, and general dental care products. Animal health is another segment, with the company producing and distributing veterinary medical supplies for livestock, aquatic species, and domestic pets. Contract manufacturing services are also available through Yuhan. Established in 1926, Yuhan Corporation is headquartered in Seoul, South Korea.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Not enough data to calculate KvantraRank
Based on consensus from external analysts. Not Kvantra's opinion.
Yuhan Corporation is a global pharmaceutical enterprise specializing in the research, development, and manufacturing of active pharmaceutical ingredients (APIs) and intermediate compounds, with operations spanning South Korea and international markets. Its extensive product portfolio includes a diverse range of pharmaceuticals such as antivirals, antibiotics, antihistamines, antidiabetics, beta-lactamase inhibitors, CNS intermediates, and PEGylated compounds. A notable offering is Revanex, an acid pump antagonist used to treat peptic ulcers and gastritis-related mucosal damage. The company also provides ethical drugs (ETC) targeting multiple therapeutic areas, including cardiovascular, digestive, genito-urinary, metabolic, respiratory, allergy, and neurological systems, alongside anti-infectives, anti-cancer treatments, hormone therapies, analgesics, anti-rheumatics, and anesthetics. Beyond prescription medications, Yuhan also markets over-the-counter (OTC) items, encompassing vitamins, minerals, liver support medications, tonics, and remedies for respiratory, digestive, dermatological, and pain conditions. Furthermore, it supplies household and personal care goods, such as cleaning agents (bleaches, detergents), pest control products, and oral hygiene solutions. The corporation maintains a dental division, supplying implants, dental equipment, consumables, and general dental care products. Animal health is another segment, with the company producing and distributing veterinary medical supplies for livestock, aquatic species, and domestic pets. Contract manufacturing services are also available through Yuhan. Established in 1926, Yuhan Corporation is headquartered in Seoul, South Korea.